United States: Amgen v. Sandoz Federal Circuit Decision

On July 21, 2015, the Federal Circuit issued a divided decision in Amgen Inc. v. Sandoz Inc.,1 interpreting two provisions of the Biologics Price Competition and Innovation Act (BPCIA).2 The Federal Circuit decided two issues: 1) whether, as Amgen contends, the BPCIA requires Sandoz, and other biosimilar applicants, to provide a complete copy of their biosimilar application and manufacturing information within twenty days after the U.S. Food and Drug Administration (FDA) accepts the application, and 2) whether Sandoz's 180-day notice of commercial marketing was premature, as it was provided before the FDA approved and licensed Zarxio® (filgrastim-sndz), Sandoz's biosimilar to Amgen's Neupogen® product (filgrastim). These issues provided the Federal Circuit with its first real opportunity to substantively interpret the provisions of the BPCIA.

The majority opinion was authored by Judge Lourie and joined in parts by Judges Chen and Newman. The majority (Judges Lourie and Chen) affirmed the district court's interpretation of the "information exchange" provision of the BPCIA, finding that biosimilar applicants are not required to provide their biosimilar applications to the Reference Product Sponsor (RPS). However, the majority (Judges Lourie and Newman) partially reversed the district court's decision by holding that the 180-day notice of commercial marketing provision of the BPCIA is ineffective unless it is provided after a biosimilar applicant receives FDA licensure. The Court's decision therefore blunts Sandoz's earlier victory at the district court.

Quoting Winston Churchill and echoing statements made during oral argument, the majority opinion described the BPCIA as "a riddle wrapped in a mystery inside an enigma,"3 and noted that the Court did their "best to unravel the riddle, solve the mystery, and comprehend the enigma." Judge Chen, in his separate opinion, similarly noted that "[t]o fulfill our judicial obligation 'to say what the law is,' we must choose from a series of imperfect choices."4 In contrast, Judge Newman wrote that the "BPCIA as enacted leaves no uncertainty as to which of its provisions are mandatory and which are permissive."5

1. The "information exchange" provision does not require biosimilar applicants to give their application to RPSs.

Paragraph (l)(2)(A) (the "information exchange" provision) of the BPCIA provides that:

Not later than twenty days after the Secretary notifies the subsection (k) applicant that the application has been accepted for review, the subsection (k) applicant shall provide to the reference product sponsor a copy of the application submitted to the Secretary under subsection (k), and such other information that describes the process or processes used to manufacture the biological product that is the subject of such application.6

The first portion of Judge Lourie's majority opinion, joined by Judge Chen, found that the "shall provide" language is permissive, rather than mandatory. Looking at the BPCIA as a whole, the majority found that the "shall" language cannot be read in isolation from the rest of the information exchange provision.7 Instead, when considering the statute as a whole, "latter provisions indicate that 'shall' in paragraph (l)(2)(A) does not mean 'must.'"8

The majority looked at other provisions of the BPCIA to determine Congress's intent in interpreting the "shall provide" language of (l)(2)(A).9 As was evident at the oral arguments, the majority's opinion indicated that the term "shall," when read in isolation, is mandatory, but like any other statutory term, its meaning is driven by context. The Court observed that the BPCIA "expressly contemplated" a situation that paralleled Sandoz's refusal to disclose their aBLA application by setting forth "consequence[s] for such failure."10 Seeing that "both 42 U.S.C. § 262(l)(9)(C) and 35 U.S.C.§ 271(e)(2)(C)(ii) are premised on a claim of patent infringement, and the BPCIA does not specify any non-patent-based remedies for a failure to comply with paragraph(l)(2)(A),"11 the majority concluded that "shall" in this instance does not institute a mandatory exchange of information. To bolster the holding, the majority stated that "mandating compliance with paragraph (l)(2)(A) in all circumstances would render paragraph (l)(9)(C) and 35 U.S.C. § 271(e)(2)(C)(ii) superfluous, and statutes are to be interpreted if possible to avoid rendering any provision superfluous."12

Judge Newman dissented from this section of the opinion, asserting that the majority disrupts the balance between the benefits and concessions made by both sides under the BPCIA. Judge Newman's dissent first noted that "Subsection (k) and subsection (l) are components of an integrated framework; to enjoy the benefits of subsection (k), the biosimilar applicant is obligated to comply with subsection (l) . . . . It is not denied that Sandoz obtained the benefit of the Amgen data in filing under subsection (k). Sandoz should be required to respect its obligations, in fidelity to the statute."13

Judge Newman's opinion also stresses textual interpretation, and criticizes the majority's failure to account for the plain language of the BPCIA. Citing firmly established Supreme Court precedent, Judge Newman asserts that "[t]he word 'shall' is ordinarily the language of command."14 Moreover, the term "shall" in the disclosure provision is followed immediately by the term "may," and thus "[w]hen the same Rule uses both 'may' and 'shall,' the normal inference is that each is used in its usual sense—the one act being permissive, the other mandatory."15

Finally, Judge Newman expresses concern about the majority's opinion regarding the alternate pathways for recourse. According to Judge Newman, the option for the RPS to file a declaratory judgment action in the event a biosimilar applicant fails to disclose its aBLA are limited to product or use claims, and do not include manufacturing process patents. Indeed, Judge Newman noted that "[a]bsent adequate factual support in a complaint for manufacturing method claims, declaratory jurisdiction may be unsupported."16

2. The "notice" provision requires biosimilar applicants to give RPSs 180 days advance notice of commercial marketing after receiving FDA licensure.

Paragraph (l)(8)(A) (the "notice" provision) provides that "[t]he subsection (k) applicant shall provide notice to the reference product sponsor not later than 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k)."17

The second part of Judge Lourie's majority opinion, joined here by Judge Newman, found that the "notice" provision of the BPCIA requires a biosimilar applicant to first receive FDA licensure before giving the statutory 180 days' notice of commercial marketing to the RPS. Thus, the majority reversed the district court's holding that Sandoz may give notice at any point after the FDA had received their biosimilar application.

The majority supported its decision by noting that "[r]equiring that a product be licensed before notice of commercial marketing ensures the existence of a fully crystallized controversy regarding the need for injunctive relief . . . . If a notice of commercial marketing could be given at any time before FDA licensure, the RPS would be left to guess the scope of the approved license and when commercial marketing would actually begin."18

While Sandoz argued that requiring the 180-day notice after FDA approval would extend Amgen's exclusivity an additionalsix months, the majority stated that this was an anomaly predicated on the fact that Amgen's 12-year exclusivity period had already expired, but that this anomaly might not become the norm.19 Moreover, the majority pointed out that "[a] statute must be interpreted as it is enacted, not especially in light of particular, untypical facts of a given case."20

Judge Chen dissented to this portion of the opinion, arguing that the majority inconsistently interpreted the term "shall" in the two separate but related sections of the BPCIA.21 "To reach that inconsistent result, the majority takes the view that (l)(8)(A) should be read in a vacuum, apart from the context and framework of subsection (l), including the language of (l)(8)(B)."22

Judge Chen also writes that the 180-day notice provision of the BPCIA cannot be considered a "standalone" provision, and instead requires an integrated reading into the remainder of the statute like the information exchange portion. "The interwoven structure of subsection (l) indicates that Congress viewed the procedures of (l)(8) as inseverable from the preceding steps in (l)."23 According to Judge Chen, if a biosimilar applicant fails to disclose its application, none of the provisions of subsections (l)(3)-(l)(8) apply: "[T]he better reading of (l)(8) is that it does not apply, just as (l)(3)-(l)(7) do not apply, when the (k) applicant fails to comply with [the disclosure requirements of] (l)(2)."24 Thus, "[j]ust as 'shall' in (l)(2) does not mean 'must,' the same is true for the 'shall' provision in (l)(8)(A), once it is read in context with the entirety of subsection (l)."25

Finally, in addressing the majority's concern that the BPCIA does not provide a remedy for non-compliance with the 180-day "notice" provision, Judge Chen concludes that additional recourse is unnecessary, because failure to comply with the disclosure requirement allows the RPS to immediately bring a declaratory judgment suit for patent infringement on any patent, including product, use, and process patents.26


The Federal Circuit's decision in the Amgen v. Sandoz case provides much needed guidance on the comprehensive statute that governs the emerging biosimilar market. Given the dissenting opinions, one would be justified in wondering how long this guidance will last, and whether the case will be taken en banc by the Federal Circuit or appealed to the Supreme Court. But as it stands, the majority's opinion provides advantages for both biosimilar applicants and RPSs. The decision makes clear that, at least for now, the BPCIA does not mandate disclosure of the aBLA, opening the door for other biosimilar applicants to forego the patent exchange procedures outlined in the statute. The decision also provides that to be effective, the 180-day notice of commercial marketing must be given after FDA approval, which, in some circumstances, may extend RPSs' exclusivity by six months.

*Thomas J. Sullivan is a Summer Associate at Finnegan.
*Connor S. Houghton is a Summer Associate at Finnegan.


1. No. 2015-1499 (Fed. Cir. July 21, 2015).

2. Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119, 804-21 (2010); see also 42 U.S.C. § 262(k), (l).

3. Slip op. at 3-4, n.1.

4. Chen Dissent at 11.

5. Newman Dissent at 7.

6. 42 U.S.C. § 262(l)(2)(A) (emphasis added).

7. Slip op. at 12.

8. Id. at 13.

9. Id. at 12.

10. Id.

11. Id. at 14.

12. Id.

13. Newman Dissent at 8-9.

14. Id. at 4 (citing Alabama v. Bozeman, 533 U.S. 146, 153 (2001)).

15. Id. at 7 (citing Anderson v. Yungkau, 329 U.S. 482, 485 (1947)).

16. Id. at 6 (citing Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009)).

17. 42 U.S.C. § 262(l)(8)(A).

18. Slip op. at 17.

19. Id. at 18.

20. Id.

21. Chen Dissent at 3.

22. Id.

23. Id. at 7.

24. Id. at 10.

25. Id. at 11.

26. Id. at 8.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Nov 2017, Seminar, London, UK

Finnegan partner Anthony Tridico will present “U.S. Patent Case Law Update” at the Chartered Institute of Patent Attorneys’ annual Patent Case Law Review.

28 Nov 2017, Seminar, Milan, Italy

Finnegan partner John Paul will present “Internet of Things: Patent Liability, Enforcement and Licensing” and will join the Mock WIPO Mediation at International Technology Transfer—Licensing and ADR, co-hosted by Licensing Executives Society and World Intellectual Property Organization.

29 Nov 2017, Seminar, Tel Aviv, Israel

Finnegan is a platinum sponsor IVC Research Center’s start-up forum, “The Most Promising Start Ups for 2017 – A Synergy of Big Data, Artificial Intelligence, Machine Vision and IoT.”

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.